Benchmark numbers for T-cell prolymphocytic leukaemia, from the only evidence there is

Design

systematic review and meta-analysis of proportions from single-arm studies and registries, GRADE assessed

Population

200 adults with T-cell prolymphocytic leukaemia for response; 363 registry patients for transplant survival

Primary outcome

response to alemtuzumab-based therapy and long-term survival after allogeneic transplant

Effect

overall response 81.9% (95% CI 66.6–91.1); long-term survival after allo-HCT 30.3% (25.8–35.3)

T-cell prolymphocytic leukaemia is rare and aggressive, and everything known about treating it comes from small single-arm series. That makes counselling difficult in a specific way: you know alemtuzumab works and that transplant is the only route to durable remission, without any pooled figure to quote. This meta-analysis of proportions assembles one.

Seven studies with 200 patients informed the response analysis. Pooled overall response to alemtuzumab-based therapy was 81.9% (95% CI 66.6–91.1) and complete response 58.5% (39.6–75.2), both with substantial heterogeneity (I² of 78% and 76%). The heterogeneity was explained by line of therapy: about 85% response frontline against 51% in relapsed or refractory disease (p<0.0001). Across three independent registries covering 363 patients, long-term survival after allogeneic haematopoietic cell transplantation was 30.3% (25.8–35.3), with no heterogeneity at all.

The authors describe these as descriptive benchmarks from low-certainty single-arm evidence, and that is exactly what they are good for. They give you something honest to say to a patient: most people respond to first-line alemtuzumab, half as many respond once the disease has relapsed, and about a third of those who reach transplant are alive long term. The frontline-versus-relapsed gap also strengthens the case for moving to transplant in first remission rather than after failure.

• Quote around 85% frontline response and 51% at relapse — the distinction matters more than the pooled figure
• Plan transplant assessment in first remission rather than after relapse
• Use the 30.3% long-term survival after transplant when consenting, not a single-centre figure
• Confirm alemtuzumab access early; supply is restricted in many settings including India
• Treat these as benchmarks for counselling, not as evidence any particular sequence is best

Why it matters

It gives a clinician treating perhaps one of these patients a decade a pooled number instead of a single case memory.

Don't overread it

This pools single-arm studies with no comparator — it describes what happens with these treatments, not that they are better than alternatives.

The statistics, in plain English

I² values of 78% and 76% mean the individual studies disagreed substantially, so the pooled response figure of 81.9% is an average across settings rather than a number to expect in your patient. That the heterogeneity was explained by line of therapy is the useful part — once you split frontline from relapsed, the disagreement makes sense. By contrast the transplant survival figure has an I² of zero across three registries, which makes 30.3% an unusually dependable number for a disease this rare.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.